Search research articles
Contact Us
Filters
Showing results (141-150 of 410) with videos related to
Page
of 41
Sort By:
Investigational New Drugs
|
November 29, 2021
A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer
Corinne Maurice-Dror, Ronan Le Moigne, Ulka Vaishampayan, et al.
Urologic Oncology
|
May 24, 2005
A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer
Eric Winquist, Malcolm J Moore, Kim N Chi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 19, 2011
A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a
K N Chi, E Beardsley, B J Eigl, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association
|
December 9, 2024
Prostate-specific antigen kinetics in Asian patients with metastatic castration-sensitive prostate cancer treated with apalutamide in the TITAN trial: A post hoc analysis
Ding-Wei Ye, Hirotsugu Uemura, Byung Ha Chung, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association
|
March 16, 2022
Safety and efficacy of apalutamide in Japanese patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo-controlled, phase III TITAN study
Hirotsugu Uemura, Gaku Arai, Hiroji Uemura, et al.
Future Oncology (London, England)
|
April 14, 2026
Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01
Arun A Azad, Neeraj Agarwal, Andrew J Armstrong, et al.
European Urology
|
October 9, 2013
Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy
Peter F A Mulders, Arturo Molina, Michael Marberger, et al.
Investigational New Drugs
|
September 28, 2013
NCIC CTG IND.181: phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies
S F Dent, K A Gelmon, K N Chi, et al.
Pediatric Blood & Cancer
|
September 22, 2012
Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors
Mark W Kieran, Charles W M Roberts, Susan N Chi, et al.
Journal of Neuro-Oncology
|
August 2, 2022
An international study evaluating the epidemiology of intracranial germ cell tumors in the native versus immigrant Japanese populations: the need for an international registry
Ashley S Plant-Fox, Tomonari Suzuki, Rosdali Y Diaz Coronado, et al.
Page
of 41
Search research articles
Search
Showing results (141-150 of 410) with videos related to
Sort By:
Page
of 41
Investigational New Drugs
|
November 29, 2021
A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer
Corinne Maurice-Dror, Ronan Le Moigne, Ulka Vaishampayan, et al.
Urologic Oncology
|
May 24, 2005
A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer
Eric Winquist, Malcolm J Moore, Kim N Chi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 19, 2011
A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a
K N Chi, E Beardsley, B J Eigl, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association
|
December 9, 2024
Prostate-specific antigen kinetics in Asian patients with metastatic castration-sensitive prostate cancer treated with apalutamide in the TITAN trial: A post hoc analysis
Ding-Wei Ye, Hirotsugu Uemura, Byung Ha Chung, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association
|
March 16, 2022
Safety and efficacy of apalutamide in Japanese patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo-controlled, phase III TITAN study
Hirotsugu Uemura, Gaku Arai, Hiroji Uemura, et al.
Future Oncology (London, England)
|
April 14, 2026
Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01
Arun A Azad, Neeraj Agarwal, Andrew J Armstrong, et al.
European Urology
|
October 9, 2013
Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy
Peter F A Mulders, Arturo Molina, Michael Marberger, et al.
Investigational New Drugs
|
September 28, 2013
NCIC CTG IND.181: phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies
S F Dent, K A Gelmon, K N Chi, et al.
Pediatric Blood & Cancer
|
September 22, 2012
Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors
Mark W Kieran, Charles W M Roberts, Susan N Chi, et al.
Journal of Neuro-Oncology
|
August 2, 2022
An international study evaluating the epidemiology of intracranial germ cell tumors in the native versus immigrant Japanese populations: the need for an international registry
Ashley S Plant-Fox, Tomonari Suzuki, Rosdali Y Diaz Coronado, et al.
Page
of 41